Ptc Therapeutics Share Price (NASDAQ: PTCT)

$49.33

▲

-0.46

(-0.92%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Ptc Therapeutics Stock chart to analyse performance

Ptc Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$49.11
Today's High:$49.97
$49.33
0.45%
Downside
Day's Volatility :1.71%
Upside
1.27%
52 Weeks Low:$30.41
52 Weeks High:$58.38
$49.33
38.35%
Downside
52 Weeks Volatility :47.91%
Upside
15.5%

Ptc Therapeutics Stock Returns

Period	Ptc Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	0.98%	3.6%	0.0%
6 Months	-6.73%	-7.7%	0.0%
1 Year	47.59%	-12.6%	0.0%
3 Years	-4.75%	9.5%	-4.7%

Ptc Therapeutics, Inc. Key Stats

Check Ptc Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$49.79
Open	$49.865
Today's High	$49.965
Today's Low	$49.11
Market Capitalization	$4.0B
Today's Volume	$906.9K
52 Week High	$58.38
52 Week Low	$30.41
Revenue TTM	$1.8B
EBITDA	$894.9M
Earnings Per Share (EPS)	$6.99
PE Ratio	7.06
Profit Margin	35.65%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-7740.12%

Stock Returns calculator for Ptc Therapeutics Stock including INR - Dollar returns

The Ptc Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Ptc Therapeutics investment value today

Current value as on today

₹1,52,935

Returns

₹52,935

(+52.93%)

Returns from Ptc Therapeutics Stock

₹47,650 (+47.65%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Ptc Therapeutics Stock

70%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Ptc Therapeutics Stock from India on INDmoney has increased by 70% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ptc Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
11.15%
BlackRock Inc
9.79%
RTW INVESTMENTS, LLC
9.76%
Armistice Capital, LLC
5.97%
Wellington Management Company LLP
5.91%
HHG PLC
4.00%

Analyst Recommendation on Ptc Therapeutics Stock

Rating

Trend

Buy

50%Buy

30%Hold

20%Sell

Based on 20 Wall street analysts offering stock ratings for Ptc Therapeutics(by analysts ranked 0 to 5 stars)

Ptc Therapeutics Share Price Target

What analysts predicted

Upside of 35.19%

Target:

$66.69

Current:

$49.33

Ptc Therapeutics share price target is $66.69, a slight Upside of 35.19% compared to current price of $49.33 as per analysts' prediction.

Ptc Therapeutics Stock Insights

Price Movement
In the last 1 year, PTCT stock has moved up by 39.6%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.17B → 178.87M (in $), with an average decrease of 84.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 866.56M → -64.84M (in $), with an average decrease of 107.5% per quarter
PTCT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 30.3%
PTCT vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 113.1%
Price to Sales
ForPTCT every $1 of sales, investors are willing to pay $2.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Ptc Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$307.0M	↑ 15.96%
Net Income	$-251.6M	↑ 96.42%
Net Profit Margin	-81.95%	↓ 33.57%

	FY20	Y/Y Change
Revenue	$380.8M	↑ 24.04%
Net Income	$-438.2M	↑ 74.17%
Net Profit Margin	-115.07%	↓ 33.12%

	FY21	Y/Y Change
Revenue	$538.6M	↑ 41.45%
Net Income	$-523.9M	↑ 19.57%
Net Profit Margin	-97.27%	↑ 17.8%

	FY22	Y/Y Change
Revenue	$698.8M	↑ 29.75%
Net Income	$-559.0M	↑ 6.7%
Net Profit Margin	-80.0%	↑ 17.27%

	FY23	Y/Y Change
Revenue	$937.8M	↑ 34.2%
Net Income	$-626.6M	↑ 12.09%
Net Profit Margin	-66.81%	↑ 13.19%

	FY24	Y/Y Change
Revenue	$806.8M	↓ 13.97%
Net Income	$-363.3M	↓ 42.02%
Net Profit Margin	-45.03%	↑ 21.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$210.1M	↓ 31.57%
Net Income	$-91.6M	↓ 41.22%
Net Profit Margin	-43.58%	↑ 7.16%

	Q2 FY24	Q/Q Change
Revenue	$186.7M	↓ 11.14%
Net Income	$-99.2M	↑ 8.3%
Net Profit Margin	-53.12%	↓ 9.54%

	Q3 FY24	Q/Q Change
Revenue	$196.8M	↑ 5.4%
Net Income	$-106.7M	↑ 7.54%
Net Profit Margin	-54.2%	↓ 1.08%

	Q4 FY24	Q/Q Change
Revenue	$213.2M	↑ 8.33%
Net Income	$-65.9M	↓ 38.22%
Net Profit Margin	-30.91%	↑ 23.29%

	Q1 FY25	Q/Q Change
Revenue	$1.2B	↑ 451.71%
Net Income	$866.6M	↓ 1415.24%
Net Profit Margin	73.68%	↑ 104.59%

	Q2 FY25	Q/Q Change
Revenue	$178.9M	↓ 84.79%
Net Income	$-64.8M	↓ 107.48%
Net Profit Margin	-36.25%	↓ 109.93%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$294.8M	↑ 16.97%

	FY20	Y/Y Change
Profit	$361.8M	↑ 22.72%

	FY21	Y/Y Change
Profit	$506.3M	↑ 39.92%

	FY22	Y/Y Change
Profit	$654.1M	↑ 29.21%

	FY23	Y/Y Change
Profit	$649.7M	↓ 0.68%

	FY24	Y/Y Change
Profit	$749.4M	↑ 15.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$143.8M	↓ 28.35%

	Q2 FY24	Q/Q Change
Profit	$168.3M	↑ 17.01%

	Q3 FY24	Q/Q Change
Profit	$185.9M	↑ 10.47%

	Q4 FY24	Q/Q Change
Profit	$251.3M	↑ 35.14%

	Q1 FY25	Q/Q Change
Profit	$1.2B	↑ 362.92%

	Q2 FY25	Q/Q Change
Profit	$163.4M	↓ 85.95%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-98.6M	↑ 256.86%
Investing Cash Flow	$-387.2M	↑ 808.73%
Financing Cash Flow	$613.2M	↑ 366.07%

	FY20	Y/Y Change
Operating Cash Flow	$-194.1M	↑ 96.75%
Investing Cash Flow	$-561.5M	↑ 45.01%
Financing Cash Flow	$668.7M	↑ 9.05%

	FY21	Y/Y Change
Operating Cash Flow	$-251.3M	↑ 29.51%
Investing Cash Flow	$219.2M	↓ 139.03%
Financing Cash Flow	$20.9M	↓ 96.88%

	FY22	Y/Y Change
Operating Cash Flow	$-356.7M	↑ 41.91%
Investing Cash Flow	$290.2M	↑ 32.39%
Financing Cash Flow	$168.0M	↑ 704.48%

	FY23	Y/Y Change
Operating Cash Flow	$-158.4M	↓ 55.58%
Investing Cash Flow	$-176.7M	↓ 160.91%
Financing Cash Flow	$646.4M	↑ 284.87%

	FY24	Y/Y Change
Operating Cash Flow	$-107.7M	↓ 32.02%
Investing Cash Flow	$44.2M	↓ 125.0%
Financing Cash Flow	$255.9M	↓ 60.42%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$70.8M	↓ 170.56%
Investing Cash Flow	$-114.9M	↑ 21.73%
Financing Cash Flow	$540.0K	↓ 99.91%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-71.5M	↓ 200.98%
Investing Cash Flow	$-65.9M	↓ 42.64%
Financing Cash Flow	$246.5M	↑ 45544.81%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-77.0M	↑ 7.75%
Investing Cash Flow	$-42.7M	↓ 35.27%
Financing Cash Flow	$-17.6M	↓ 107.15%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-30.0M	↓ 61.03%
Investing Cash Flow	$267.7M	↓ 727.33%
Financing Cash Flow	$26.5M	↓ 250.17%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$870.1M	↓ 2999.96%
Investing Cash Flow	$-184.4M	↓ 168.87%
Financing Cash Flow	$9.4M	↓ 64.45%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-58.3M	↓ 106.7%
Investing Cash Flow	$-422.0M	↑ 128.9%
Financing Cash Flow	$4.0M	↓ 57.91%

Ptc Therapeutics Technicals Summary

Sell

Neutral

Buy

Ptc Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Ptc Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ptc Therapeutics, Inc.	-5.37%	-6.73%	47.59%	-4.75%	-0.38%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ptc Therapeutics, Inc.	7.06	7.06	0.81	7.93	-77.4	0.24	NA	-2.6
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ptc Therapeutics, Inc.	Buy	$4.0B	-0.38%	7.06	35.65%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Ptc Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Organization	Ptc Therapeutics
Employees	939
CEO	Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Industry	Health Technology

Key Management of Ptc Therapeutics, Inc.

Name	Title
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.	CEO & Director
Dr. Allan Steven Jacobson Ph.D.	Co-Founder & Independent Director
Mr. Pierre Gravier M.S.	Chief Financial Officer
Dr. Neil Almstead Ph.D.	Chief Technical Operations Officer
Mr. Eric Pauwels	Chief Business Officer
Dr. Lee Golden M.D., Ph.D.	Executive VP & Chief Medical Officer
Ms. Linda Montella Carter	Senior VP & Chief Information Officer
Mr. Mark Elliott Boulding J.D.	Executive VP & Chief Legal Officer
Ms. Jane Baj	Vice President of Corporate Communications
Ms. Hege Sollie-Zetlmayer	Chief Human Resources Officer

Important FAQs about investing in PTCT Stock from India :

What is Ptc Therapeutics share price today?

Ptc Therapeutics share price today is $49.33 as on August 30, 2025 at 1:29 am IST at the close of the market. Ptc Therapeutics share today touched a day high of $49.97 and a low of $49.11.

What is the 52 week high and 52 week low for Ptc Therapeutics share?

Ptc Therapeutics share touched a 52 week high of $58.38 and a 52 week low of $30.41. Ptc Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $49.33, lower by 15.5% versus the 52 week high.

How to invest in Ptc Therapeutics Stock (PTCT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Ptc Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ptc Therapeutics Shares that will get you 0.0304 shares as per Ptc Therapeutics share price of $49.33 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Ptc Therapeutics Stock (PTCT) from India?

Indian investors can start investing in Ptc Therapeutics (PTCT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Ptc Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Ptc Therapeutics share’s latest price of $49.33 as on August 30, 2025 at 1:29 am IST, you will get 0.2027 shares of Ptc Therapeutics. Learn more about fractional shares .

What are the returns that Ptc Therapeutics has given to Indian investors in the last 5 years?

Ptc Therapeutics stock has given -0.38% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?